Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 5/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 5/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.38 |
| ▸ | PPARD | Q03181 | 4/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5104284 | 1.00 | LMNA (0.41) | LMNADGAT2HDAC3HDAC1HDAC2 | |
| SCHEMBL5103509 | 0.95 | EPHX2 (0.41) | LMNADGAT2HDAC3HDAC1HDAC2 | |
| SCHEMBL14192034 | 0.95 | EPHX2 (0.41) | LMNADGAT2HDAC3HDAC1HDAC2 | |
| SCHEMBL14192036 | 0.95 | CFTR (0.44) | LMNADGAT2CFTRMEN1POLB | |
| SCHEMBL5107522 | 0.95 | CFTR (0.44) | LMNADGAT2CFTRMEN1POLB | |
| SCHEMBL14192035 | 0.90 | LMNA (0.46) | LMNAMEN1POLBKMT2ARIPK1 | |
| SCHEMBL5107357 | 0.90 | LMNA (0.46) | LMNAMEN1POLBKMT2ARIPK1 | |
| SCHEMBL14192032 | 0.90 | KMT2A (0.40) | LMNADGAT2CFTRMEN1POLB | |
| SCHEMBL5112994 | 0.90 | KMT2A (0.40) | LMNADGAT2CFTRMEN1POLB | |
| SCHEMBL5114091 | 0.88 | CFTR (0.39) | DGAT2CFTRPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080124402-A1 | N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080124402-A1 | N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124402-A1 | N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators | SHBG, AR, NR5A1 | LMNA 1068/4885DGAT2 3284/4885HDAC3 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.